Cytori Therapeutics, Inc. acquired substantially all of the assets of Azaya Therapeutics Incorporated for $20.2 million.
January 18, 2017
Share
Cytori Therapeutics, Inc. (NasdaqCM:CYTX) acquired substantially all of the assets of Azaya Therapeutics Incorporated for $20.2 million on January 16, 2017. Cytori Therapeutics, Inc. (NasdaqCM:CYTX) will issue approximately $2 million of shares, of which approximately $1.5 million will be paid at closing and approximately $0.5 million will be deposited into escrow account. Cytori Therapeutics, Inc will assume $2 million debt of Azaya Therapeutics debt and will pay $16.3 million based upon achievement of certain net sales milestones for ATI-0918. The transaction is subject to receive approval of shareholders of Azaya Therapeutics and receipt of consent from its secured lender, Oxford Finance, LLC.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
PLUS THERAPEUTICS, INC. 
